Tumor marker levels in post-chemotherapy cystic masses: clinical implications for patients with germ cell tumors.
OBJECTIVE
Increased tumor markers after induction chemotherapy for patients with germ cell tumor usually represent systemic disease and consequently second line chemotherapy is instituted, while retroperitoneal lymph node dissection (RPLND) is reserved for patients with marker normalization. We report the concentration of alpha-fetoprotein (AFP) and human chorionic gonadotropin (HCG) in the fluid of post-chemotherapy cystic masses to evaluate this as a potential source for serum marker elevation.


METHODS
From March 2002 to December 2002, 11 consecutive patients with post-chemotherapy cystic masses underwent RPLND. Following resection, aspirated fluid was analyzed for AFP and HCG. Only 5 post-chemotherapy RPLNDs were performed in patients with increased serum tumor markers, including the 3 patients in our study. Patients with increasing tumor markers and/or multifocal disease with noncystic residual masses after induction chemotherapy underwent salvage chemotherapy despite teratomatous elements in the primary tumor.


RESULTS
All 11 patients had teratoma in the orchiectomy specimen and retroperitoneum, including one with malignant transformation. Cystic fluid markers were increased in all patients, 9 of 9 with HCG (range 7.0 to 6,880) and 9 of 11 with AFP (27.5 to 521.2). Two patients with an increased serum AFP before surgery (47.9 and 31.6) had cyst levels of 73.5 and 790.4 respectively. Both serum markers normalized postoperatively. One patient with increased pre-RPLND serum HCG (11.6) had a cyst level of 233. HCG continued to increase postoperatively and the patient died of disease. The remaining 10 patients remain disease free.


CONCLUSIONS
Fluid from cystic teratoma contains variably elevated levels of HCG and AFP in all patients and appears to be independent of serum marker level or pathology. It is possible that a "slow leak" of fluid from cystic teratoma may explain elevated serum markers in selected patients with teratoma and thus may potentially avoid second line chemotherapy.
Beck
Stephen D W
SD
Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
Patel
Manish I
MI
Sheinfeld
Joel
J
D014408:Biomarkers, Tumor / Q000032:analysis*; D006063:Chorionic Gonadotropin / Q000032:analysis*; D020420:Cyst Fluid / Q000737:chemistry; D003560:Cysts / Q000737:chemistry* / Q000175:diagnosis* / Q000601:surgery; D018237:Germinoma / Q000188:drug therapy*; D006801:Humans; D008197:Lymph Node Excision; D008297:Male; D012187:Retroperitoneal Space; D013733:Testicular Diseases / Q000175:diagnosis / Q000601:surgery; D013736:Testicular Neoplasms / Q000188:drug therapy*; D000509:alpha-Fetoproteins / Q000032:analysis*
D014408:Biomarkers, Tumor; D006063:Chorionic Gonadotropin; D000509:alpha-Fetoproteins